Original Article
Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels
N Engl J Med 2005; 353:1564-1573October 13, 2005
- Abstract
Background
We investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.
Methods
A group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay.
Results
There were no significant differences in mean (±SE) serum osteopontin levels between age-matched subjects with exposure to asbestos and subjects without exposure to asbestos (30±3 ng per milliliter and 20±4 ng per milliliter, respectively; P=0.06). In the group with exposure to asbestos, elevated serum osteopontin levels were associated with pulmonary plaques and fibrosis (56±13 ng per milliliter) but not with normal radiographic findings (21±5 ng per milliliter), plaques alone (23±3 ng per milliliter), or fibrosis alone (32±7 ng per milliliter) (P=0.004). Serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos (133±10 ng per milliliter vs. 30±3 ng per milliliter, P<0.001). Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma. An analysis of serum osteopontin levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with mesothelioma had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of osteopontin per milliliter. Subgroup analysis comparing patients with stage I mesothelioma with subjects with exposure to asbestos revealed a sensitivity of 84.6 percent and a specificity of 88.4 percent at a cutoff value of 62.4 ng of osteopontin per milliliter.
Conclusions
Serum osteopontin levels can be used to distinguish persons with exposure to asbestos who do not have cancer from those with exposure to asbestos who have pleural mesothelioma.
Media in This Article
Figure 1
Median Survival and Progression-free Survival, According to the Stage of Pleural Mesothelioma.Figure 2
Immunohistochemical Staining for Osteopontin in Two Samples of Pleural Mesothelioma.Article Activity
- Article
Pleural mesothelioma is an asbestos-related cancer with a median survival of 8 to 18 months.1 Persons with asbestos-related nonmalignant disease are an ideal cohort in which to study biomarkers for the early detection of pleural mesothelioma, because they are at high risk for the tumor; have had a measurable, identifiable exposure to the carcinogen; reside in defined and well-studied regions; and have a high rate of compliance in long-term follow-up studies.2
Retrospective studies of small numbers of patients with pleural mesothelioma have attempted to identify biomarkers that predate symptoms in a high-risk population. These markers include tissue polypeptide antigen, carcinoembryonic antigen, hyaluronic acid and ferritin,3 hyaluronic acid alone,4-11 cytokeratins such as soluble cytokeratin 19 fragment,12-16 CA-125,17 and soluble mesothelin-related protein.18
We have used gene-expression arrays to predict survival and recurrence patterns in patients with pleural mesothelioma19 and to seek markers that would be useful for screening and diagnosis of pleural mesothelioma. The most promising biomarker was osteopontin, a glycoprotein that is overexpressed in lung,20 breast,21 colorectal,22 gastric,23 and ovarian24-26 cancer and in melanoma.27 Osteopontin mediates cell-matrix interactions and cell signaling through binding with integrin and CD44 receptors28 and is regulated by proteins in cell-signaling pathways that are associated with asbestos-induced carcinogenesis. Moreover, high levels of osteopontin correlate with tumor invasion, progression, and metastases. Sandhu et al. reported that osteopontin is up-regulated in asbestos-induced tumors in a rat model of asbestos carcinogenesis and in cells exposed to asbestos in vitro.29
We undertook the present study to test our hypothesis that osteopontin is a useful biomarker in pleural mesothelioma and, more specifically, to compare serum levels of osteopontin in a cohort of subjects with asbestos-related nonmalignant disease with preoperative levels in patients with surgically treated pleural mesothelioma.
Methods
Study Population
We studied three groups of subjects: 69 subjects with a history of exposure to asbestos, evidence of asbestosis, or both; 45 current or former smokers with no exposure to asbestos who were undergoing screening bronchoscopy; and 76 patients with pleural mesothelioma. All subjects provided serum samples and written informed consent. The study was approved by the ethics committee of each participating institution.
Subjects with Exposure to Asbestos
From July to September 2004, we enrolled 69 subjects with a history of exposure to asbestos, radiographic changes consistent with the presence of asbestosis, or both who were seen at the Center for Occupational and Environmental Medicine, Royal Oak, Michigan. Entry criteria for this cohort were similar to those described by Cullen et al.2 Both exposure to asbestos and the duration of exposure were documented with the use of the American Thoracic Society Division of Lung Diseases 78 Adult questionnaire.30
Subjects either were employed in a trade associated with established habitual exposure to asbestos for which there is a documented increase in the risk of asbestos-related diseases (including insulation manufacturing or installation, sheet-metal work, plumbing, plasterboard application, shipfitting, electrical work on ships, boilermaking, and ship scaling)31 or had occupational exposure to asbestos (as determined by the American Thoracic Society Division of Lung Diseases 78 Adult questionnaire) and radiographic evidence of changes consistent with a diagnosis of nonmalignant asbestos-related disease. These radiographic findings included benign pleural disease, defined as thickening or fibrotic plaques on the pleural surfaces of both lungs, with or without diffuse lung fibrosis manifested by small, irregular shadows in both lungs.
A plain chest radiograph was obtained from each subject and interpreted by a single trained radiologist (a B reader certified by the National Institute for Occupational Safety and Health) who was unaware of the patient's exposure status and who was proficient in the classification of chest radiographs for pneumoconioses according to the International Labor Office Classification System. The B reader specifically commented on the presence or absence of pleural changes, including plaques and lung fibrosis. Lung fibrosis was interpreted according to the International Classification of Radiographs of Pneumoconioses (available at www.ilo.org/publns). This 12-point system classifies fibrosis according to the size and number of abnormal areas (from 0/0 to 3/3 in each lung); only results of 1/0 or greater were classified as indicative of asbestosis.
Of the 69 subjects in the group exposed to asbestos, 57 (83 percent) had been exposed as the result of working in an asbestos-related trade for at least five years, 7 (10 percent) had had such exposure for less than five years, and 5 (7 percent) had radiographic evidence of abnormalities consistent with the occurrence of exposure to asbestos but had no such exposure documented during an interview. The professions of the 64 participants with exposure to asbestos were as follows: 11 were foundry workers, 7 were pipe fitters, 7 were in building and construction, 6 had passive exposure in the construction business or from contact with a family member, 5 were involved in brake assembly or repair, 4 were involved in boiler repair, 4 had exposure to vermiculite insulation, 3 were machinist grinders, 3 were plumbers, 2 were in the tool and die industry, 2 were shipbuilders, 2 were millwrights, 2 were firefighters, 2 were brick makers, 2 were electricians, and 2 were involved in asbestos removal. Radiographic evidence of fibrosis was found in 23 of the 69 (33 percent), and pleural plaques were found in 50 of the 69 (72 percent); 6 participants with 5 to 37 years of exposure had no radiographic abnormalities, 53 had either plaques or fibrosis, and 10 had both plaques and fibrosis.
Subjects with No Exposure to Asbestos
To document serum osteopontin levels in an unexposed, but similar population, we obtained serum samples from 25 current smokers and 20 former smokers (age, 33 to 74 years) who were undergoing screening bronchoscopy as an entry criterion for a chemoprevention trial. Occupational histories were obtained from all these subjects to document the absence of known exposure to asbestos; all these participants had normal chest radiographs.
Patients with Pleural Mesothelioma
Serum was obtained from 76 patients who were scheduled to undergo cytoreductive surgery for pleural mesothelioma, according to a protocol approved by the Wayne State University Human Investigation Committee (D1420). The oldest serum sample was obtained 77 months before analysis, and the most recent sample 3 months before. Exposure to asbestos was documented on the basis of an occupational history in 59 of the 76 patients (78 percent). All patients underwent complete surgical staging according to the staging system of the International Mesothelioma Interest Group (IMIG)32: 13 had stage I, 20 had stage II, and 43 had stage III disease. All were followed with the use of computed tomography of the chest every three to four months until death or to a follow-up date in April 2005. Tumors were classified as epithelial in 50 patients, sarcomatoid in 4, and mixed in 22 by two of the authors. Table 1Table 1
Demographic Characteristics of Patients with Pleural Mesothelioma and Subjects with Asbestos-Related Nonmalignant Disease. lists the characteristics of the group exposed to asbestos and the group with pleural mesothelioma.Immunohistochemistry
Immunohistochemical analysis was performed on a multitissue pleural-mesothelioma array, consisting of 2-mm representative areas of resected tumor and normal-tissue controls. Thirty-eight of the 76 samples of pleural tumors studied were on the array. The other 38 were not available when the array was constructed, since they were conscripted for asbestos litigation cases. Immunohistochemical analysis was performed with the use of the standard avidin–biotin complex technique. The primary antibody, a monoclonal antibody against osteopontin (clone OP3 N, Vector Laboratories), was applied to the array at a dilution of 1:150 for 90 minutes at room temperature. The secondary antibody, anti–mouse IgG (Vector Laboratories), was applied at a dilution of 1:200 for 30 minutes at room temperature. A positive control and a negative control (obtained by omitting the secondary antibody) were included in each run. Samples were scored separately for staining intensity on a three-point scale (with a score of 1 indicating low intensity, and a score of 3 high intensity) and for the percentage of positive tumor cells (with a score of 1 indicating 10 percent or less, a score of 2 indicating 11 to 49 percent, and a score of 3 indicating 50 percent or more).
Osteopontin Enzyme-Linked Immunosorbent Assay
The Human Osteopontin Assay Kit (ImmunoBiological Laboratories) was used to determine the level of serum osteopontin; all samples were coded. Each specimen was tested in duplicate, and the results were quantitated in nanograms per milliliter with the use of a standard curve.
Statistical Analysis
Kaplan–Meier survival plots and log-rank tests were used to assess differences in survival according to the stage of disease among the patients with pleural mesothelioma. The ability of serum osteopontin levels to distinguish the patients with pleural mesothelioma from the subjects with asbestos-related nonmalignant disease was evaluated by means of descriptive statistics and receiver-operating-characteristic (ROC) curves.33,34 The area under the ROC curve (AUC) was calculated, and 95 percent confidence intervals were used to test the hypothesis that the theoretical AUC is 0.5. An AUC with a confidence interval that did not include the 0.5 value was considered evidence that the laboratory test had some ability to distinguish between the two groups.34,35 We calculated differences between groups by using analysis of variance and multiple regression analysis in a stepwise fashion, entering only variables with a P value of less than 0.05 in the model. All statistical analyses were performed with the use of MedCalc software.
Results
Survival According to the Stage of Pleural Mesothelioma
To determine whether the patients with mesothelioma in this study had outcomes similar to those in other series, survival and time-to-progression curves based on IMIG staging status were generated. Figure 1Figure 1
Median Survival and Progression-free Survival, According to the Stage of Pleural Mesothelioma. shows significant differences in survival and progression according to stage; these results are consistent with those of other studies that used the IMIG staging system.36-38 Immunohistochemical Findings
Tumor tissue was available for osteopontin staining from 38 of the 76 patients with mesothelioma; 36 of the 38 samples were positive for osteopontin (Figure 2Figure 2
Immunohistochemical Staining for Osteopontin in Two Samples of Pleural Mesothelioma.). They showed cytoplasmic staining in at least 50 percent of tumor cells, and the staining intensity ranged from 1 in the case of 13 samples to 3 in the case of 15 samples; 8 samples had a staining intensity of 2. Osteopontin was seen in all pleural-mesothelioma variants: 19 of 20 epithelial tumors, 15 of 16 mixed tumors, and 2 of 2 sarcomatoid tumors. Lung parenchyma and adjacent normal pleura were negative for osteopontin, fibroblasts in tumor-associated stroma were infrequently weakly positive, and the media and intima of vessels showed weak positivity.Osteopontin Levels
Subjects Exposed to Asbestos and Subjects without Exposure
The mean (±SE) serum level of osteopontin in the entire group of subjects who were exposed to asbestos was 30±3 ng per milliliter (range, 2 to 221; 95 percent confidence interval, 23 to 36) and did not differ significantly from that in subjects without exposure to asbestos (20±4 ng per milliliter, P=0.06). The levels in age-matched controls with no exposure to asbestos and normal radiographs did not differ significantly according to age from those in the group exposed to asbestos (younger than 50 years of age, 12±5 ng per milliliter and 25±11 ng per milliliter, respectively; 95 percent confidence interval for the difference, –16 to 41; P=0.34; 50 to 60 years of age, 19±6 ng per milliliter and 25±5 ng per milliliter; 95 percent confidence interval for the difference, –12 to 22; P=0.56; and older than 60 years of age, 24±5 ng per milliliter and 32±4 ng per milliliter; 95 percent confidence interval for the difference, –23 to 7; P=0.29) (Figure 3AFigure 3
Mean (±SE) Serum Osteopontin Levels According to Exposure Status and Age, Sex, Years of Exposure to Asbestos, and Radiographic Findings.).In the group with exposure to asbestos, there were no significant differences in osteopontin levels according to sex (P=0.19) (Figure 3B) or the presence or absence of pleural plaques (P=0.88) (Figure 3D). The subgroup with lung fibrosis had a significantly higher mean level of osteopontin than the subgroup without fibrosis (43 ng per milliliter vs. 23 ng per milliliter; 95 percent confidence interval for the difference, 7 to 33; P=0.004) (Figure 3D), and the mean levels were significantly higher with 10 or more years of exposure than with fewer than 10 years of exposure (34 ng per milliliter vs. 16 ng per milliliter; 95 percent confidence interval for the difference, 4 to 33; P=0.02) (Figure 3C). The highest levels of serum osteopontin were found in subjects who had both plaques and fibrosis (56±13 ng per milliliter). Serum osteopontin levels were significantly lower in age-matched unexposed controls than in subjects with asbestos exposure and plaques and fibrosis (mean age in both groups, 64±3 years): 14±6 ng per milliliter vs. 56±13 ng per milliliter (P=0.03). Among the subjects with exposure to asbestos, osteopontin levels were significantly lower in subjects with a normal chest radiograph (21±5 ng per milliliter), subjects with plaques (23±3 ng per milliliter), and subjects with fibrosis (32±7 ng per milliliter) than in those who had plaques and fibrosis (56±13 ng per milliliter, P=0.004).
A multiple regression analysis that included age, the duration of exposure to asbestos, the presence or absence of fibrosis, the presence or absence of plaques, and the International Labor Organization radiography score was performed. Only the duration of exposure to asbestos and the radiographic findings were independently associated with osteopontin levels (P=0.001 and P<0.001, respectively), with zero-order correlation coefficients of 0.357 and 0.399, respectively.
Patients with Pleural Mesothelioma
The mean serum osteopontin level in the group with pleural mesothelioma differed significantly from that in the group exposed to asbestos (133±10 ng per milliliter [range, 6 to 385; 95 percent confidence interval, 113 to 154] vs. 30±3 ng per milliliter [range, 2 to 221; 95 percent confidence interval, 23 to 36], P<0.001). There were no significant differences in mean serum osteopontin levels among patients with stage I mesothelioma (147±26 ng per milliliter; range, 10 to 341; 95 percent confidence interval, 92 to 204), stage II mesothelioma (158±22 ng per milliliter; range, 14 to 385; 95 percent confidence interval, 99 to 216), or stage III mesothelioma (118±12 ng per milliliter; range, 4 to 302; 95 percent confidence interval, 83 to 145; P>0.15 for all comparisons); however, the means in all these stages differed significantly from the mean in the group exposed to asbestos (30±3 ng per milliliter; range, 2 to 221; 95 percent confidence interval, 23 to 36; P<0.001). Moreover, serum osteopontin levels in the subjects with exposure to asbestos and plaques and fibrosis differed significantly from those in the patients with pleural mesothelioma (56±13 ng per milliliter vs. 133±10 ng per milliliter; 95 percent confidence interval for the difference, 49 to 114; P<0.001).
Mean osteopontin levels were similar in men and women with mesothelioma (136±12 ng per milliliter and 125±21 ng per milliliter, respectively; 95 percent confidence interval for the difference, –61 to 39; P=0.66) and did not vary according to the histologic characteristics of the tumor (128±13 ng per milliliter among those with epithelial tumors, as compared with 133±18 ng per milliliter among those with nonepithelial tumors; 95 percent confidence interval for the difference, –28 to 59; P=0.49) or the history of asbestos exposure (151±24 ng per milliliter among those with exposure, as compared with 128±12 ng per milliliter among those without exposure; 95 percent confidence interval for the difference, –73 to 28; P=0.37).
ROC Curves
ROC analyses comparing the subjects with exposure to asbestos with patients with pleural mesothelioma showed an AUC of 0.888 (95 percent confidence interval, 0.826 to 0.934) (Figure 4AFigure 4
Sensitivity and Specificity of Serum Osteopontin for Distinguishing Patients with Pleural Mesothelioma from Subjects with Asbestos-Related Nonmalignant Disease.). Subgroup analyses showed that the AUC values for patients with stage I, those with stage II, those with stage I or II, and those with stage III pleural mesothelioma were 0.906, 0.925, 0.917, and 0.865, respectively, as compared with subjects with exposure to asbestos. A cutoff value of 48.3 ng of osteopontin per milliliter (sensitivity of 77.6 percent and specificity of 85.5 percent) had the highest accuracy (minimal false negative and false positive results) for confirming mesothelioma (Figure 4C). For the purpose of screening (i.e., early detection for mesothelioma), a cutoff value with the highest sensitivity (95 to 99 percent) might be most appropriate independent of specificity, and at a cutoff value of 10.9 ng of osteopontin per milliliter, the sensitivity was 96.1 percent, with a specificity of 23.2 percent (Figure 4B). If screening were for the detection of stage I disease alone, a cutoff value of 9.5 ng of osteopontin per milliliter would provide 100 percent sensitivity, with a specificity of 21.7 percent. The most accurate cutoff value, however, for the detection of a stage I mesothelioma (with a sensitivity of 84.6 percent and a specificity of 88.4 percent) was 62.4 ng of osteopontin per milliliter.Discussion
The lifetime risk of pleural mesothelioma in a population with exposure to asbestos ranges from 4.5 to 10.0 percent. Workers at risk for high levels of exposure are miners, factory workers, carpenters, electricians, shipfitters, ships' electricians, boilermakers, insulation manufacturers, railroad workers, gas-mask manufacturers, and pipe insulators.39 It has been estimated that as many as 7.5 million construction workers in the United States have used construction materials containing asbestos for fireproofing of buildings, acoustic control, ductwork, and pipe and boiler installation.40 Moreover, asbestos is still a hazard for an estimated 1.3 million workers in the construction industry in the United States and for workers involved in the maintenance of buildings and equipment.41 At present, there are no economically feasible, validated methods to screen all these persons at risk, since the estimated number of new cases of mesothelioma in the United States per year is only 2500 to 3000 (an age-adjusted incidence of 2 cases per 100,000 persons).42
The median survival after the diagnosis of pleural mesothelioma is 9 to 12 months; in advanced cases, resection of the tumor can prolong survival by about 3 months. Patients with stage IA disease, however, can survive for five or more years if the tumor is promptly resected. Unfortunately, the difficulty in detecting early disease means that less than 5 percent of patients with pleural mesothelioma present with stage IA disease. Hence, a marker or series of biomarkers that can predict the development of mesothelioma or detect pleural mesothelioma in its early stages in populations with exposure to asbestos would be of considerable value.
We found that osteopontin levels in the 69 subjects with exposure to asbestos did not differ significantly from those in age-matched controls and that osteopontin levels reflected the duration of occupational exposure and the extent of radiographic abnormalities. As compared with the subjects with exposure to asbestos, patients with pleural mesothelioma had significantly higher serum osteopontin levels. We carefully documented the type of exposure history, using a standardized occupational–environmental questionnaire, and interpretation of the radiographs by a B reader allowed classification of the population with exposure to asbestos according to important risk factors for pleural mesothelioma, including the duration of exposure.
A multiple regression analysis revealed that the duration of exposure and the radiographic findings were the most important influences on serum osteopontin levels and that longer exposure and more extensive radiographic abnormalities were significantly associated with elevated osteopontin levels. Fibrotic changes, but not pleural plaques, were also associated with elevated levels of osteopontin. The combination of radiographic findings and serum levels of osteopontin could be used to stratify the risk of pleural mesothelioma in populations with exposure to asbestos; close surveillance might be indicated in workers with a long history of exposure, pleural plaques and fibrosis, and elevated serum osteopontin levels.
The most important result of our study is the apparent ability of an enzyme-linked immunosorbent assay (ELISA) for osteopontin to identify early pleural mesothelioma (stage I). This finding, if confirmed, would have immediate clinical applications, because the use of therapy could potentially influence survival among patients with stage I pleural mesothelioma.
Immunohistochemical analysis showed that osteopontin was present in the tumor cells of pleural mesothelioma and not in the stroma. This finding provides support for the specificity of osteopontin as a marker for transformed mesothelial cells.
Osteopontin is being investigated as a biomarker in other types of cancer. Using immunohistochemical analysis, Coppola et al.43 found high levels of osteopontin in gastric, colorectal, pancreatic, lung, and ovarian carcinomas, among others, and a strong correlation between osteopontin levels and the pathological stage. Schneider et al.44 found that high tissue levels of osteopontin, measured by means of a real-time polymerase-chain-reaction assay, correlated with decreased survival among patients with resected non–small-cell lung cancer. In both patients with pancreatic cancer45 and patients with breast cancer,46 serum osteopontin levels, as measured by ELISA, were elevated in patients with new or progressive neoplasms. The levels of osteopontin in these studies differed from those seen with our commercially available ELISA owing to technical differences, including our use of a monoclonal antibody system as opposed to a polyclonal ELISA and the measurement of serum osteopontin rather than plasma osteopontin, which led to levels that were lower than the manufacturer's standard levels for plasma determinations.
Our data suggest that serum osteopontin levels could be used to discriminate between persons with exposure to asbestos who do not have early pleural mesothelioma and those with exposure to asbestos who do have early pleural mesothelioma, regardless of the histologic type of the mesothelioma. Moreover, the fact that the AUC approached 0.9 suggests that the osteopontin level has a positive predictive power equivalent to that of CA-125 for ovarian cancer.47 Osteopontin levels, however, are also elevated in other types of cancers, including gastrointestinal, laryngeal, and urinary neoplasms, and these cancers have been weakly associated with exposure to asbestos. The hypothesis that the osteopontin level may be increased in asbestos workers in whom cancers other than mesothelioma develop is being investigated. Nevertheless, we suggest that asbestos workers with high osteopontin levels who do not appear to have mesothelioma should be evaluated to rule out the presence of other cancers. Our data do not justify the global use of osteopontin measurements in persons other than those who have been exposed to asbestos as defined here or who have radiographic evidence of pleural disease.
Supported in part by a Department of Veterans Affairs Merit Review Award (to Dr. Pass) and by patients' donations to the Thoracic Oncology Program of the Karmanos Cancer Institute.
Source Information
From the Departments of Surgery (H.I.P., N.T., A.W.), Pathology (F.L.), Medicine (M.H.), and Computer Science (Z.L.) and the Center for Molecular Genetics (D.L.), Wayne State University, Karmanos Cancer Institute, John A. Dingell Veterans Hospital, Detroit; the Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University, Maywood, Ill. (M.C.); and the Laboratory of Tumor Metastasis and Angiogenesis, Van Andel Research Institute, Grand Rapids, Mich. (C.W.).
Address reprint requests to Dr. Pass at the NYU School of Medicine, Department of Cardiothoracic Surgery, 530 1st Ave., Suite 9V, New York, NY 10016, or at harvey.pass@med.nyu.edu.
- References
References
1
Martino D ,Pass HI . Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5:290-298
CrossRef | Medline2
Cullen MR ,Barnett MJ ,Balmes JR , et al. Predictors of lung cancer among asbestos-exposed men in the {beta}-carotene and Retinol Efficacy Trial. Am J Epidemiol 2005;161:260-270
CrossRef | Web of Science | Medline3
Ebert W ,Hoppe M ,Muley T ,Drings P . Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Anticancer Res 1997;17:2875-2878
Web of Science | Medline4
Pettersson T ,Froseth B ,Riska H ,Klockars M . Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988;94:1037-1039
CrossRef | Web of Science | Medline5
Frebourg T ,Lerebours G ,Delpech B , et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104-2107
CrossRef | Web of Science | Medline6
Roboz J ,Chahinian AP ,Holland JF ,Silides D ,Szrajer L . Early diagnosis and monitoring of transplanted human malignant mesothelioma by serum hyaluronic acid. J Natl Cancer Inst 1989;81:924-928
CrossRef | Web of Science | Medline7
Chiu B ,Churg A ,Tengblad A ,Pearce R ,McCaughey WT . Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984;54:2195-2199
CrossRef | Web of Science | Medline8
Boersma A ,Degand P ,Biserte G . Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Eur Physiopathol Respir 1980;16:41-45
Medline9
Hellstrom PE ,Friman C ,Teppo L . Malignant mesothelioma of 17 years' duration with high pleural fluid concentration of hyaluronate. Scand J Respir Dis 1977;58:97-102
Medline10
Thylen A ,Hjerpe A ,Martensson G . Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001;92:1224-1230
CrossRef | Web of Science | Medline11
Pluygers E ,Baldewyns P ,Minette P ,Beauduin M ,Gourdin P ,Robinet P . Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations. Eur J Cancer Prev 1992;1:129-138
CrossRef | Medline12
Lee YC ,Knox BS ,Garrett JE . Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust N Z J Med 1999;29:765-769
CrossRef | Medline13
Paganuzzi M ,Onetto M ,Marroni P , et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001;119:1138-1142
CrossRef | Web of Science | Medline14
Schouwink H ,Korse CM ,Bonfrer JM ,Hart AA ,Baas P . Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999;25:25-32
CrossRef | Web of Science | Medline15
Marukawa M ,Hiyama J ,Shiota Y , et al. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma. Acta Med Okayama 1998;52:119-123
Web of Science | Medline16
Bonfrer JM ,Schouwink JH ,Korse CM ,Baas P . Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 1997;17:2971-2973
Web of Science | Medline17
Almudevar BE ,Garcia-Rostan Perez GM ,Garcia Bragado F ,Jimenez C . Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women: a case report with differential diagnosis and review of the literature. Histopathology 1997;31:267-273
CrossRef | Web of Science | Medline18
Robinson BW ,Creaney J ,Lake R , et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616
CrossRef | Web of Science | Medline19
Pass HI ,Liu Z ,Wali A , et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004;10:849-859
CrossRef | Web of Science | Medline20
Fedarko NS ,Jain A ,Karadag A ,Van Eman MR ,Fisher LW . Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-4066
Web of Science | Medline21
Singhal H ,Bautista DS ,Tonkin KS , et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-611
Web of Science | Medline22
Ding L ,Zheng S . Expression and clinical significance of osteopontin in colorectal cancer and liver metastatic tissues. Zhonghua Wai Ke Za Zhi 2002;40:773-775
Medline23
Ue T ,Yokozaki H ,Kitadai Y , et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-132
CrossRef | Web of Science | Medline24
Schorge JO ,Drake RD ,Lee H , et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004;10:3474-3478
CrossRef | Web of Science | Medline25
Brakora KA ,Lee H ,Yusuf R , et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004;93:361-365
CrossRef | Web of Science | Medline26
Kim JH ,Skates SJ ,Uede T , et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-1679
CrossRef | Web of Science | Medline27
Denhardt D . Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124:xvi-xviii
CrossRef | Web of Science | Medline28
Wai PY ,Kuo PC . The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-241
CrossRef | Web of Science | Medline29
Sandhu H ,Dehnen W ,Roller M ,Abel J ,Unfried K . mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 2000;21:1023-1029
CrossRef | Web of Science | Medline30
Ferris BG . Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978;118:1-120
Web of Science | Medline31
Selikoff IJ ,Churg J ,Hammond EC . Asbestos exposure and neoplasia. CA Cancer J Clin 1984;34:48-56
CrossRef | Web of Science | Medline32
Rusch VW . A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1-12
CrossRef | Web of Science | Medline33
Metz CE . Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-298
CrossRef | Web of Science | Medline34
Zweig MH ,Campbell G . Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577[Erratum, Clin Chem 1993;39:1589.]
Web of Science | Medline35
Hanley JA ,McNeil BJ . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36
Web of Science | Medline36
Pass HI ,Temeck BK ,Kranda K ,Steinberg SM ,Feuerstein IR . Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-317
CrossRef | Web of Science | Medline37
Rusch VW ,Venkatraman ES . Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-1804
CrossRef | Web of Science | Medline38
Rusch VW ,Venkatraman ES . The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-825
CrossRef | Web of Science | Medline39
Roggli VL ,Sharma A ,Butnor KJ ,Sporn T ,Vollmer RT . Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002;26:55-65
CrossRef | Web of Science | Medline40
Schottenfeld D, Fraumeni JF Jr. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, 1982.
41
Safety and health topics: asbestos. Washington, D.C.: National Institute for Occupational Safety and Health, 2003.
42
Weill H ,Hughes JM ,Churg AM . Changing trends in US mesothelioma incidence. Occup Environ Med 2004;61:438-441
CrossRef | Web of Science | Medline43
Coppola D ,Szabo M ,Boulware D , et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184-190
CrossRef | Web of Science | Medline44
Schneider S ,Yochim J ,Brabender J , et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004;10:1588-1596
CrossRef | Web of Science | Medline45
Koopmann J ,Fedarko NS ,Jain A , et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-491
Web of Science | Medline46
Martinetti A ,Bajetta E ,Ferrari L , et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 2004;11:771-779
CrossRef | Web of Science | Medline47
McIntosh MW ,Drescher C ,Karlan B , et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15
CrossRef | Web of Science | Medline
- Citing Articles (97)
Citing Articles
1
Michele Carbone, Bevan H. Ly, Ronald F. Dodson, Ian Pagano, Paul T. Morris, Umran A. Dogan, Adi F. Gazdar, Harvey I. Pass, Haining Yang. (2012) Malignant mesothelioma: Facts, Myths, and Hypotheses. Journal of Cellular Physiology 227:1, 44-58
CrossRef2
Ying Wang, Arun K. Rishi, Wenjuan Wu, Lisa Polin, Sunita Sharma, Edi Levi, Steven Albelda, Harvey I. Pass, Anil Wali. (2011) Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Molecular and Cellular Biochemistry 357:1-2, 83-94
CrossRef3
Kevin Hollevoet, Kristiaan Nackaerts, Robert Gosselin, Walter De Wever, Lionel Bosquée, Paul De Vuyst, Paul Germonpré, Eliane Kellen, Catherine Legrand, Yoshiro Kishi, Joris R. Delanghe, Jan P. van Meerbeeck. (2011) Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma. Journal of Thoracic Oncology 6:11, 1930-1937
CrossRef4
P.A. Zucali, G.L. Ceresoli, F. De Vincenzo, M. Simonelli, E. Lorenzi, L. Gianoncelli, A. Santoro. (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treatment Reviews 37:7, 543-558
CrossRef5
Jenette Creaney, Deborah Yeoman, Arthur William Musk, Nicholas de Klerk, Steven J. Skates, Bruce W.S. Robinson. (2011) Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma—Which is best?. Lung Cancer 74:1, 55-60
CrossRef6
Shusai Yamada, Chiharu Tabata, Rie Tabata, Kazuya Fukuoka, Takashi Nakano. (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clinical Chemistry and Laboratory Medicine 49:10, 1721-1726
CrossRef7
Alfonso Cristaudo, Alessandra Bonotti, Silvia Simonini, Agnese Vivaldi, Giovanni Guglielmi, Nicolino Ambrosino, Antonio Chella, Marco Lucchi, Alfredo Mussi, Rudy Foddis. (2011) Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 6:9, 1587-1593
CrossRef8
Risa Maeda, Chiharu Tabata, Rie Tabata, Ryoji Eguchi, Yoshihiro Fujimori, Takashi Nakano. (2011) Is Serum Thioredoxin-1 a Useful Clinical Marker for Malignant Pleural Mesothelioma?. Antioxidants & Redox Signaling 15:3, 685-689
CrossRef9
Stefan B. Watzka, Florian Posch, Harvey I. Pass, Margaret Huflejt, David Bernhard, Gregory E. Hannigan, Michael R. Müller. (2011) Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma. The Journal of Thoracic and Cardiovascular Surgery 142:2, 384-389
CrossRef10
Paolo Andrea Zucali, Rita De Sanctis, Fabio De Vincenzo, Matteo Simonelli, Elena Lorenzi, Matteo Perrino, Armando Santoro. (2011) Treatment of malignant pleural mesothelioma: current status and future directions. Clinical Investigation 1:7, 999-1018
CrossRef11
Jeffrey Levin, Paul Rountree. 2011. Core Curriculum for Practicing Physicians Related to Asbestos. , 593-615.
CrossRef12
Pieter H. Anborgh, Jennifer C. Mutrie, Alan B. Tuck, Ann F. Chambers. (2011) Pre- and post-translational regulation of osteopontin in cancer. Journal of Cell Communication and Signaling 5:2, 111-122
CrossRef13
Krishna B Sriram, Vandana Relan, Belinda E Clarke, Edwina E Duhig, Ian A Yang, Rayleen V Bowman, YC Gary Lee, Kwun M Fong. (2011) Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology 7:6, 737-752
CrossRef14
Yoshitaka Sekido. (2011) Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathology International 61:6, 331-344
CrossRef15
Jennifer E. Below, Nancy J. Cox, Naomi K. Fukagawa, Ari Hirvonen, Joseph R. Testa. (2011) Factors that Impact Susceptibility to Fiber-Induced Health Effects. Journal of Toxicology and Environmental Health, Part B 14:1-4, 246-266
CrossRef16
Veronica Balatti, Stefania Maniero, Manuela Ferracin, Angelo Veronese, Massimo Negrini, Gloria Ferrocci, Fernanda Martini, Mauro G. Tognon. (2011) MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 6:5, 844-851
CrossRef17
Tara Sabo-Attwood, Maria E. Ramos-Nino, Maria Eugenia-Ariza, Maximilian B. MacPherson, Kelly J. Butnor, Pamela C. Vacek, Sean P. McGee, Jessica C. Clark, Chad Steele, Brooke T. Mossman. (2011) Osteopontin Modulates Inflammation, Mucin Production, and Gene Expression Signatures After Inhalation of Asbestos in a Murine Model of Fibrosis. The American Journal of Pathology 178:5, 1975-1985
CrossRef18
S van der Bij, E Schaake, H Koffijberg, J A Burgers, B A J M de Mol, K G M Moons. (2011) Markers for the non-invasive diagnosis of mesothelioma: a systematic review. British Journal of Cancer 104:8, 1325-1333
CrossRef19
Steven Chuan-Hao Kao, Glen Reid, Nico van Zandwijk, Douglas W Henderson, Sonja Klebe. (2011) Molecular biomarkers in malignant mesothelioma: state of the art. Pathology 43:3, 201-212
CrossRef20
Alfonso Cristaudo, Alessandra Bonotti, Silvia Simonini, Rossella Bruno, Rudy Foddis. (2011) Soluble markers for diagnosis of malignant pleural mesothelioma. Biomarkers in Medicine 5:2, 261-273
CrossRef21
M. Betti, D. Ferrante, M. Padoan, S. Guarrera, M. Giordano, A. Aspesi, D. Mirabelli, C. Casadio, F. Ardissone, E. Ruffini, P.G. Betta, R. Libener, R. Guaschino, G. Matullo, E. Piccolini, C. Magnani, I. Dianzani. (2011) XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case–control study. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 708:1-2, 11-20
CrossRef22
Fabien Gueugnon, Sabrina Leclercq, Christophe Blanquart, Christine Sagan, Laurent Cellerin, Martine Padieu, Christian Perigaud, Arnaud Scherpereel, Marc Gregoire. (2011) Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma. The American Journal of Pathology 178:3, 1033-1042
CrossRef23
Giuseppe Mastrangelo, Gianluca Marangi, Maria N Ballarin, Silvia Michilin, Aline SC Fabricio, Flavio Valentini, John H Lange, Ugo Fedeli, Luca Cegolon, Massimo Gion. (2011) Osteopontin, asbestos exposure and pleural plaques: a cross-sectional study. BMC Public Health 11:1, 220
CrossRef24
Eun-Kee Park, Anthony R. Johnson, Deborah H. Yates, Paul S. Thomas. (2011) Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases. Clinical Chemistry and Laboratory Medicine 49:1, 147-150
CrossRef25
Noriko Hirayama, Chiharu Tabata, Rie Tabata, Risa Maeda, Akihiro Yasumitsu, Shusai Yamada, Kozo Kuribayashi, Kazuya Fukuoka, Takashi Nakano. (2011) Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respiratory Medicine 105:1, 137-142
CrossRef26
Georgios T. STATHOPOULOS. (2011) Translational advances in pleural malignancies. Respirology 16:1, 53-63
CrossRef27
Eun-Kee Park, Paul S. Thomas, Deborah H. Yates. (2010) Biomarkers for early detection of mesothelioma in asbestos-exposed subjects. Clinical Chemistry and Laboratory Medicine 48:11, 1673-1674
CrossRef28
Abie H. Mendelsohn, Chi K. Lai, I Peter Shintaku, David A. Elashoff, Steven M. Dubinett, Elliot Abemayor, Maie A. St. John. (2010) Histopathologic findings of HPV and p16 positive HNSCC. The Laryngoscope 120:9, 1788-1794
CrossRef29
Ying Wang, Arun K. Rishi, Vineshkumar T. Puliyappadamba, Sunita Sharma, Huanjie Yang, Adi Tarca, Q. Ping Dou, Fulvio Lonardo, John C. Ruckdeschel, Harvey I. Pass, Anil Wali. (2010) Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemotherapy and Pharmacology 66:3, 455-466
CrossRef30
Pieter H. Anborgh, Jennifer C. Mutrie, Alan B. Tuck, Ann F. Chambers. (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. Journal of Cellular and Molecular Medicine 14:8, 2037-2044
CrossRef31
H. Yang, Z. Rivera, S. Jube, M. Nasu, P. Bertino, C. Goparaju, G. Franzoso, M. T. Lotze, T. Krausz, H. I. Pass, M. E. Bianchi, M. Carbone. (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proceedings of the National Academy of Sciences 107:28, 12611-12616
CrossRef32
Seiji Kurata, Masatoshi Ishibashi, Koichi Azuma, Hayato Kaida, Shinzo Takamori, Kiminori Fujimoto, Maiko Kobayashi, Yasumitsu Hirose, Hisamichi Aizawa, Naofumi Hayabuchi. (2010) Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease. Japanese Journal of Radiology 28:6, 446-452
CrossRef33
Mark J. Utell, L. Daniel Maxim. (2010) Refractory ceramic fiber (RCF) toxicity and epidemiology: A review. Inhalation Toxicology 22:6, 500-521
CrossRef34
K Tajima, R Ohashi, Y Sekido, T Hida, T Nara, M Hashimoto, S Iwakami, K Minakata, T Yae, F Takahashi, H Saya, K Takahashi. (2010) Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene 29:13, 1941-1951
CrossRef35
Akihiro Yasumitsu, Chiharu Tabata, Rie Tabata, Noriko Hirayama, Aki Murakami, Shusai Yamada, Takayuki Terada, Shinichiro Iida, Kunihiro Tamura, Kazuya Fukuoka, Kozo Kuribayashi, Takashi Nakano. (2010) Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 5:4, 479-483
CrossRef36
Panagiota Georgiadou, Efstathios K. Iliodromitis, Fotios Kolokathis, Christos Varounis, Vassilis Gizas, Manolis Mavroidis, Yassemi Capetanaki, Harisios Boudoulas, Dimitrios T. Kremastinos. (2010) Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. European Journal of Clinical Investigation 40:4, 288-293
CrossRef37
Qian Hu, Shinya Akatsuka, Yoriko Yamashita, Hiroki Ohara, Hirotaka Nagai, Yasumasa Okazaki, Takashi Takahashi, Shinya Toyokuni. (2010) Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Laboratory Investigation 90:3, 360-373
CrossRef38
Alex J. Rai, Raja M. Flores, Anu Mathew, Rita Gonzalez-Espinoza, Matthew Bott, Marc Ladanyi, Valerie Rusch, Martin Fleisher. (2010) Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clinical Chemistry and Laboratory Medicine 48:2, 271-278
CrossRef39
S. Sackmann. (2010) Klinik und Diagnostik des malignen Pleuramesothelioms. Der Pneumologe 7:1, 19-27
CrossRef40
Takeshi Mimura, Yoshihiro Miyata, Yasuhiro Tsutani, Riki Okita, Yukari Kawasaki, Kei Kushitani, Yukio Takeshima, Kouki Inai, Kouji Arihiro, Morihito Okada. (2010) Pleural Biopsy for a Definitive Diagnosis of Malignant Pleural Mesothelioma. Haigan 50:2, 130-135
CrossRef41
Yasuhiro Kuramitsu, Hiromu Miyamoto, Toshiyuki Tanaka, Xiulian Zhang, Masanori Fujimoto, Kazuhiro Ueda, Toshiki Tanaka, Kimikazu Hamano, Kazuyuki Nakamura. (2009) Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. PROTEOMICS 9:22, 5078-5089
CrossRef42
H.M. Salahudeen, E.T.D. Hoey, R.J. Robertson, M.J. Darby. (2009) CT appearances of pleural tumours. Clinical Radiology 64:9, 918-930
CrossRef43
Charalampos MOSCHOS, Ilias PORFIRIDIS, Ioannis PSALLIDAS, Androniki KOLLINTZA, Georgios T. STATHOPOULOS, Spyros A. PAPIRIS, Charis ROUSSOS, Ioannis KALOMENIDIS. (2009) Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology 14:5, 716-722
CrossRef44
Jenette Creaney, Bruce WS Robinson. (2009) Serum and pleural fluid biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine 15:4, 366-370
CrossRef45
Harvey I. Pass, Michele Carbone. (2009) Current Status of Screening for Malignant Pleural Mesothelioma. Seminars in Thoracic and Cardiovascular Surgery 21:2, 97-104
CrossRef46
Sergey V. Ivanov, Alla V. Ivanova, Chandra M.V. Goparaju, Yuanbin Chen, Amanda Beck, Harvey I. Pass. (2009) Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochemical and Biophysical Research Communications 382:3, 514-518
CrossRef47
Paolo Andrea Zucali, Fabio De Vincenzo, Matteo Simonelli, Armando Santoro. (2009) Future developments in the management of malignant pleural mesothelioma. Expert Review of Anticancer Therapy 9:4, 453-467
CrossRef48
Steven G. Gray, Dean A. Fennell, Luciano Mutti, Kenneth J. O’Byrne. (2009) In Arrayed Ranks. Journal of Thoracic Oncology 4:3, 411-425
CrossRef49
Francisco Rodríguez-Panadero, Myriam Aguilar Pérez, Manuel Alejandro Muñoz Moya, María Isabel Asensio Cruz. (2009) Manejo de la patología pleural. Archivos de Bronconeumología 45, 22-27
CrossRef50
Rina Ohashi, Ken Tajima, Ri Cui, Tao Gu, Okio Hino, Kazu Shiomi, Hideaki Miyamoto, Kazuto Nishio, Kazuhisa Takahashi. (2009) Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions in Vitro. Haigan 49:4, 368-375
CrossRef51
Tomonori Hirashima, Kazuya Fukuoka, Toyoaki Hida, Kunimitsu Kawahara, Takumi Kishimoto, Akihide Matsumura, Kikuo Nakano, Morihito Okada, Takashi Nakano. (2009) Soluble Mesothelin-related Peptides (SMRP) as a Biomarker for Malignant Pleural Mesothelioma. Haigan 49:4, 380-385
CrossRef52
Ryoko Sherriff-Tadano, Ayako Tanaka, Toshiaki Yoshida, Tazuko Obara, Chisano Yoshikawa, Ruriko Wakeshima, Chie Furushima. (2009) Anxiety, Depression, and Clinical Profile of Patients Who Visited Asbestos Center. Journal of Japan Academy of Nursing Science 29:2, 29-37
CrossRef53
Goutam Chakraborty, Shalini Jain, Tushar V. Patil, Gopal C. Kundu. (2008) Down-regulation of osteopontin attenuates breast tumour progression in vivo. Journal of Cellular and Molecular Medicine 12:6a, 2305-2318
CrossRef54
Joachim Schneider, Hans Hoffmann, Hendrik Dienemann, Felix J. F. Herth, Michael Meister, Thomas Muley. (2008) Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer. Journal of Thoracic Oncology 3:11, 1317-1324
CrossRef55
Marcello Deraco, David Bartlett, Shigeki Kusamura, Dario Baratti. (2008) Consensus statement on peritoneal mesothelioma. Journal of Surgical Oncology 98:4, 268-272
CrossRef56
Oluf Dimitri Roe, Jenette Creaney, Steinar Lundgren, Erik Larsson, Helmut Sandeck, Paolo Boffetta, Tom Ivar Nilsen, Bruce Robinson, Kristina Kjaerheim. (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case–control study. Lung Cancer 61:2, 235-243
CrossRef57
Jenette Creaney, Deborah Yeoman, Yvonne Demelker, Amanda Segal, A W. Musk, Steven J. Skates, Bruce W. S. Robinson. (2008) Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. Journal of Thoracic Oncology 3:8, 851-857
CrossRef58
Michael D Zervos, Costas Bizekis, Harvey I Pass. (2008) Malignant mesothelioma 2008. Current Opinion in Pulmonary Medicine 14:4, 303-309
CrossRef59
Zeyana Rivera, Oriana Strianese, Pietro Bertino, Haining Yang, Harvey Pass, Michele Carbone. (2008) The relationship between simian virus 40 and mesothelioma. Current Opinion in Pulmonary Medicine 14:4, 316-321
CrossRef60
Holly Janes, Margaret S. Pepe. (2008) Matching in Studies of Classification Accuracy: Implications for Analysis, Efficiency, and Assessment of Incremental Value. Biometrics 64:1, 1-9
CrossRef61
Michel M. van den Heuvel, Catharina M. Korse, Johannes M.G. Bonfrer, Paul Baas. (2008) Non-invasive diagnosis of pleural malignancies: The role of tumour markers. Lung Cancer 59:3, 350-354
CrossRef62
Derrick Nguyen, Sang-Joon Lee, Edward Libby, Claire Verschraegen. (2008) Rate of Thromboembolic Events in Mesothelioma. The Annals of Thoracic Surgery 85:3, 1032-1038
CrossRef63
Andrew J Kaufman, Harvey I Pass. (2008) Current concepts in malignant pleural mesothelioma. Expert Review of Anticancer Therapy 8:2, 293-303
CrossRef64
J.-C. Pairon, P. Andujar, M. Matrat, J. Ameille. (2008) Cancers respiratoires professionnels. Revue des Maladies Respiratoires 25:2, 193-207
CrossRef65
John E. Heffner, Jeffrey S. Klein. (2008) Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions. Mayo Clinic Proceedings 83:2, 235-250
CrossRef66
J. E. Heffner, J. S. Klein. (2008) Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions. Mayo Clinic Proceedings 83:2, 235-250
CrossRef67
Harvey I. Pass, Anil Wali, Naimei Tang, Alla Ivanova, Sergey Ivanov, Michael Harbut, Michele Carbone, Jeffrey Allard. (2008) Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions. The Annals of Thoracic Surgery 85:1, 265-272
CrossRef68
Hideyuki Nishi, Kazuhiro Washio, Masayuki Mano. (2008) Clinical diagnosis of malignant pleural mesothelioma. The Journal of the Japanese Association for Chest Surgery 22:1, 18-23
CrossRef69
Laurent Greillier, Philippe Astoul. (2008) Mesothelioma and Asbestos-Related Pleural Diseases. Respiration 76:1, 1-15
CrossRef70
Takumi Kishimoto, Kenichi Gemba, Hideyuki Nishi, Nobukazu Fujimoto, Nobuyoshi Shimizu. (2008) Diagnosis and Treatment of Pleural Mesothelioma. Haigan 48:3, 165-170
CrossRef71
Jeffrey A. Tsou, Janice S. Galler, Anil Wali, Wei Ye, Kimberly D. Siegmund, Susan Groshen, Peter W. Laird, Sally Turla, Michael N. Koss, Harvey I. Pass, Ite A. Laird-Offringa. (2007) DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 58:2, 220-230
CrossRef72
M Carbone, S M Albelda, V C Broaddus, R M Flores, G Hillerdal, M-C Jaurand, K Kjaerheim, H I Pass, B Robinson, A Tsao. (2007) Eighth International Mesothelioma Interest Group. Oncogene 26:49, 6959-6967
CrossRef73
M. Payer, T. von Briel. (2007) Intradural pleural malignant mesothelioma. Acta Neurochirurgica 149:10, 1053-1056
CrossRef74
L. Greillier, A. Scherpereel, P. Astoul. (2007) Mésothéliome pleural : conséquences de la stadification sur la stratégie thérapeutique. Revue des Maladies Respiratoires 24:8, 146-156
CrossRef75
Giovanni L. Ceresoli, Arturo Chiti, Paolo A. Zucali, Federico Cappuzzo, Fabio De Vincenzo, Raffaele Cavina, Marcello Rodari, Dario Poretti, Fabio Romano Lutman, Armando Santoro. (2007) Assessment of tumor response in malignant pleural mesothelioma. Cancer Treatment Reviews 33:6, 533-541
CrossRef76
Giorgio Vittorio Scagliotti, Giovanni Selvaggi. (2007) Advances in diagnosis and treatment of malignant pleural mesothelioma. Oncology Reviews 1:2, 91-102
CrossRef77
Zhong-Qian Li, Thorsten Verch, W Jeffrey Allard. (2007) MESOMARK
in vitro diagnostic test for mesothelioma. Expert Opinion on Medical Diagnostics 1:1, 137-142
CrossRef78
Yoon Soo Chang, Hyung Jung Kim, Joon Chang, Chul Min Ahn, Sung Kyu Kim, Se Kyu Kim. (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:3, 373-380
CrossRef79
Mika Suzuki, Evangeline Mose, Christine Galloy, David Tarin. (2007) Osteopontin Gene Expression Determines Spontaneous Metastatic Performance of Orthotopic Human Breast Cancer Xenografts. The American Journal of Pathology 171:2, 682-692
CrossRef80
Arnaud Scherpereel, YC Gary Lee. (2007) Biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine 13:4, 339-343
CrossRef81
Hiroshi Okamoto. (2007) Osteopontin and cardiovascular system. Molecular and Cellular Biochemistry 300:1-2, 1-7
CrossRef82
A B Frey, A Wali, H Pass, F Lonardo. (2007) Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 50:6, 720-726
CrossRef83
Tristan D. Yan, Raffit Hassan, Laura Welch, Paul H. Sugarbaker. (2007) Advances in diffuse malignant peritoneal mesothelioma. Oncology Reviews 1:1, 53-64
CrossRef84
Michele Carbone, Salih Emri, A. Umran Dogan, Ian Steele, Murat Tuncer, Harvey I. Pass, Y. Izzettin Baris. (2007) A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nature Reviews Cancer 7:2, 147-154
CrossRef85
T. V. Torchynska, A. Diaz Cano, M. Dybiec, S. Ostapenko, M. Morales Rodrigez, S. Jiménez-Sandoval, Y. Vorobiev, C. Phelan, A. Zajac, T. Zhukov, T. Sellers. (2007) Raman scattering and SEM study of bio-conjugated core-shell CdSe/ZnS quantum dots. physica status solidi (c) 4:2, 241-243
CrossRef86
Dario Baratti, Shigeki Kusamura, Antonia Martinetti, Ettore Seregni, Daniela G. Oliva, Barbara Laterza, Marcello Deraco. (2007) Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. Annals of Surgical Oncology 14:2, 500-508
CrossRef87
Pierre P. Massion, Richard M. Caprioli. (2006) Proteomic Strategies for the Characterization and the Early Detection of Lung Cancer. Journal of Thoracic Oncology 1:9, 1027-1039
CrossRef88
A. Scherpereel. (2006) Brèves actualités sur la plèvre. Revue des Maladies Respiratoires 23:5, 110-114
CrossRef89
Masahiro Maeda, Okio Hino. (2006) Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers. Pathology International 56:11, 649-654
CrossRef90
Kazu Shiomi, Hideaki Miyamoto, Tatsuya Segawa, Yoshiaki Hagiwara, Akinobu Ota, Masahiro Maeda, Kazuhisa Takahashi, Kimihiko Masuda, Yukinori Sakao, Okio Hino. (2006) Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Science 97:9, 928-932
CrossRef91
O. Hagemeyer, H. Otten, T. Kraus. (2006) Asbestos consumption, asbestos exposure and asbestos-related occupational diseases in Germany. International Archives of Occupational and Environmental Health 79:8, 613-620
CrossRef92
Maria E. Ramos-Nino, Joseph R. Testa, Deborah A. Altomare, Harvey I. Pass, Michele Carbone, Maurizio Bocchetta, Brooke T. Mossman. (2006) Cellular and molecular parameters of mesothelioma. Journal of Cellular Biochemistry 98:4, 723-734
CrossRef93
Sophie D. West, Y.C. Gary Lee. (2006) Management of Malignant Pleural Mesothelioma. Clinics in Chest Medicine 27:2, 335-354
CrossRef94
Wei Cao, Yong-Jun Liu. (2006) Opn: key regulator of pDC interferon production. Nature Immunology 7:5, 441-443
CrossRef95
Jenette Creaney, Hanne Christansen, Richard Lake, A Bill Musk, Nick de Klerk, Bruce W.S. Robinson. (2006) Soluble Mesothelin Related Protein in Mesothelioma. Journal of Thoracic Oncology 1:2, 172-174
CrossRef96
(2006) Asbestos Exposure and Serum Osteopontin. New England Journal of Medicine 354:3, 304-305
Full Text97
Cullen, Mark R., . (2005) Serum Osteopontin Levels — Is It Time to Screen Asbestos-Exposed Workers for Pleural Mesothelioma?. New England Journal of Medicine 353:15, 1617-1618
Full Text
- Letters
